Company intelligence / Profile preview

Fennec Pharmaceuticals Inc.

Durham, North Carolina, United States of Americainvestors.fennecpharma.com ↗

Ownership: Public · FENC
Employees: ~36
Development stage: Commercial

Overview

Fennec's lead product PEDMARK/PEDMARQSI (sodium thiosulfate injection) is FDA-approved for reducing the risk of ototoxicity associated with cisplatin treatment in pediatric patients. Clinical trials showed significant reduction in hearing loss in patients receiving PEDMARK compared to those without (21% vs 73% in one study, 33% vs 63% in another)[8].

Therapeutic areas: Oncology
Modalities: Small molecules (sodium thiosulfate)
Industry: Biotech

Drug pipeline

5 assets

sodium thiosulfate

Approved

4 more assets in the full pipeline.

Request access →

Financials

Market cap: $432.5M
Total revenue: $17.9M
Enterprise value: $391.2M

Beyond the preview

Go deeper on Fennec Pharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fennec Pharmaceuticals Inc..

Explore the full profile